Morphologic transformation of human breast epithelial cells MCF-10A: dependence on an oxidative microenvironment and estrogen/epidermal growth factor receptors.
BACKGROUND
MCF-10A, immortalized but non-transformed human breast epithelial cells, are widely used in research examining carcinogenesis. The studies presented here were initiated with the observation that MCF-10A cells left in continuous culture for prolonged periods without re-feeding were prone to the development of transformed foci. We hypothesized that the depletion of labile culture components led to the onset of processes culminating in the observed cell transformation. The purpose of this study was to define the factors which promoted transformation of this cell line.


RESULTS
Changes in levels of phenol red (PHR), hydrocortisone (HC), and epidermal growth factor (EGF) with or without estrogen treatment indicated that both oxidative stress- and estrogen receptor alpha (ERα)-mediated pathways contribute to cell transformation. Gene array and Western blotting analyses of cells maintained in our laboratory and of those from other sources documented detectable ERα and ERbeta (ERβ) in this ERα-negative cataloged cell line. Results also indicate the possibility of a direct association of EGF receptor (EGFR) and ERα in these cells as well as the formation and high induction of a novel ternary complex that includes ERβ (ERα/ERβ/EGFR) in cells grown under conditions facilitating transformation.


CONCLUSIONS
Our studies resulted in the development of a growth protocol where the effects of chronic, physiologically relevant alterations in the microenvironment on cellular transformation were examined. From our results, we were able to propose a model of transformation within the MCF-10A cell line in which oxidative stress, ER and EGFR play essential roles. Overall, our work indicates that the immediate microenvironment of cells exerts powerful growth cues which ultimately determine their transformation potential.
Yusuf
Rita
R
Department of Environmental Medicine, NYU School of Medicine, PHL Room 802, 550 First Avenue, New York, NY 10016, USA. Krystyna.Frenkel@nyumc.org.
Frenkel
Krystyna
K
Cancer Res. 1996 May 1;56(9):2039-44
8616848
Breast J. 2003 Sep-Oct;9(5):361-73
12968955
Biomed Pharmacother. 2003 Dec;57(10):447-51
14637387
J Natl Cancer Inst. 2001 Feb 7;93(3):214-9
11158190
J Natl Cancer Inst Monogr. 2000;(27):135-45
10963625
Carcinogenesis. 1994 Sep;15(9):1979-84
7923593
Mol Pharmacol. 1994 Jun;45(6):1259-67
8022418
J Steroid Biochem Mol Biol. 2003 Oct;87(1):1-25
14630087
Cancer. 1983 Jun 15;51(12 Suppl):2426-9
6850519
Eur J Cancer. 1996 Jun;32A(7):1209-14
8758255
Mol Endocrinol. 2003 Mar;17(3):309-17
12554774
Metabolism. 2001 May;50(5):548-52
11319715
J Endocrinol. 2000 May;165(2):371-8
10810301
Toxicol Appl Pharmacol. 2008 Oct 1;232(1):78-85
18640140
J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):327-32
12361722
Cancer Res. 1994 Nov 1;54(21):5515-7
7923187
Int J Cancer. 2001 May 1;92(3):333-7
11291067
Breast Cancer Res. 2002;4(5):197-201
12223124
Carcinogenesis. 1994 Jul;15(7):1421-7
8033320
Proc Natl Acad Sci U S A. 1986 Apr;83(8):2496-500
3458212
Science. 2004 Feb 13;303(5660):1007-10
14963329
Chem Biol Interact. 1986 Sep;59(2):173-84
3769051
Am J Pathol. 2009 Mar;174(3):1065-74
19179608
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5550-5
11331784
Mol Pharmacol. 1983 Mar;23(2):278-81
6682170
Endocrinology. 1995 Aug;136(8):3512-8
7628388
Semin Perinatol. 1979 Jul;3(3):299-311
392771
J Steroid Biochem Mol Biol. 2002 Feb;80(2):231-8
11897506
Jpn J Cancer Res. 2001 Oct;92(10):1093-101
11676860
Ann N Y Acad Sci. 1993 Nov 30;698:1-20
8279746
Int J Cancer. 1998 May 18;76(4):563-70
9590135
J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):49-61
10819504
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):89-96
17113977
Cancer Res. 1989 Feb 1;49(3):576-80
2783381
N Engl J Med. 2001 Jan 25;344(4):276-85
11172156
J Nutr Sci Vitaminol (Tokyo). 2000 Feb;46(1):1-6
10868346
J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):143-51
10882300
J Biol Chem. 2003 Jan 24;278(4):2701-12
12421825
Cancer Res. 2006 Aug 15;66(16):7991-8
16912174
J Cell Biol. 1983 Aug;97(2):455-8
6350318
Endocrine. 2001 Nov;16(2):73-81
11887937
Cancer Res. 2003 Nov 15;63(22):7825-33
14633709
Biochem Biophys Res Commun. 1987 Feb 13;142(3):724-31
3827898
Lancet Oncol. 2002 Oct;3(10):611-9
12372723
Steroids. 2005 May-Jun;70(5-7):372-81
15862820
J Natl Cancer Inst Monogr. 2000;(27):75-93
10963621
Mutat Res. 1994 Mar 1;305(2):253-64
7510036
Chem Res Toxicol. 2008 Jan;21(1):93-101
18052105
J Natl Cancer Inst Monogr. 2000;(27):67-73
10963620
Am J Physiol. 1998 Nov;275(5):F691-702
9815127
J Biol Chem. 2001 Oct 12;276(41):37974-9
11495909
Hypertension. 1998 Dec;32(6):1083-8
9856978
Cancer Res. 1999 Sep 1;59(17):4276-84
10485472
Mutat Res. 2003 Nov;544(2-3):173-8
14644319
Mol Cancer Res. 2005 Mar;3(3):151-62
15798095
Mol Carcinog. 1996 Jul;16(3):149-56
8688150
J Clin Oncol. 2001 Jun 15;19(12):3111-6
11408508
Braz J Med Biol Res. 1994 Feb;27(2):541-6
8081279
Cancer Lett. 1996 Jan 2;98(2):219-25
8556712
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3294-6
8622931
Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):867-72
10548314
Mol Endocrinol. 2005 Nov;19(11):2660-70
15976008
Nutr Cancer. 1986;8(3):171-84
3016668
Biochim Biophys Acta. 2006 Aug;1766(1):63-78
16675129
Int J Cancer. 1990 May 15;45(5):920-7
2335395
Int J Cancer. 2006 Apr 15;118(8):1862-8
16287077
Cancer Lett. 1999 Aug 3;142(2):185-93
10463775
Am J Pathol. 1999 Dec;155(6):1811-5
10595909
Anticancer Res. 1991 Mar-Apr;11(2):737-43
2064328
Breast Cancer Res Treat. 2001 Jan;65(2):179-87
11261834
Ann N Y Acad Sci. 1995 Sep 30;768:91-100
8526389
Environ Health Perspect. 1997 Apr;105 Suppl 3:619-24
9168005
Metabolism. 1998 Jul;47(7):788-91
9667222
Eur J Cancer Prev. 1997 Feb;6(1):3-10
9161806